With New Strategy, Alnylam Again Shuffles Its Pipeline
January 13, 2011
With New Strategy, Alnylam Again Shuffles Its Pipeline
"As part of our … strategy, we have made portfolio decisions to focus our investments in our highest-value activities and on programs with exciting potential for addressing major unmet medical needs," Alnylam President and COO Barry Greene said in a statement.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam to Release Phase II ATTR Data, Launch Expansion Trial in Coming Months
May 9, 2013 / Gene Silencing News - Tekmira Provides Pipeline Update, Eyes Agricultural Market
February 14, 2013 / Gene Silencing News - Alnylam Publishes Phase I Data on Liver Cancer Drug
January 31, 2013 / Gene Silencing News - Alnylam Adds New Program to Pipeline as It Shelves Anemia Candidate
January 10, 2013 / Gene Silencing News - Alnylam Forms Alliance with Genzyme in ATTR, Adds Another Notch to Partnership Belt
October 25, 2012 / Gene Silencing News